Onabotulinumtoxin a injection with or without hydrodistension for treatment of bladder pain syndrome

Arrom, Laura Mateu; Ruiz, Cristina Gutiérrez; Palou, Joan; Errando‐Smet, Carlos

doi:10.1007/s00192-020-04451-w

Cited by 4 publications

(4 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Arrom et al achieved success in 63% of patients with intravesical BoNT/ A. [24] Also, Wang et al found improvement in 47.5% of patients in their study. [25] Patients who had not benefited from the treatments were evaluated for other invasive methods.…”

Section: Discussionmentioning

confidence: 77%

See 1 more Smart Citation

Efficacy of transcutaneous tibial nerve stimulation in the treatment of bladder pain syndrome

Alkış¹,

Aras²,

Sevim³

et al. 2022

Current Urology

View full text Add to dashboard Cite

Background: This study aimed to demonstrate the effectiveness of transcutaneos tibial nerve stimulation (TTNS) in the treatment of bladder pain syndrome (BPS). Materials and methods: The data of 16 female patients, diagnosed with BPS in our clinic between 2019 and 2021 and had TTNS twice a week for 12 weeks, were retrospectively analyzed. Results: The mean age of the patients was 46.00 ± 13.11 years, and the mean body mass index was 26.43 ± 3.07 kg/m 2 . After the treatment, the median day time frequency of the patients decreased from 13.37 (3.69) to 10.25 (4.56) (p < 0.001). Nocturia also decreased after treatment from 4.37 (1.81) to 3.00 (1.94) (p = 0.001). The median voiding volume increased by 26.5 mL (p = 0.001). The median of the patients' visual analog scale scores decreased after treatment (median of visual analog scale score changed from interquartile range 8 [1] to 7 [4]) (p = 0.001). In addition, the median interquartile range interstitial cystitis symptom index scores decreased from 17 (4) to 15 (10) (p = 0.002). Conclusions: In this study it was demonstrated that TTNS is an alternative method that can be successfully applied before invasive methods in the treatment of BPS.

show abstract

Section: Discussionmentioning

confidence: 77%

“…Up to 40% of patients benefited from intravesical BoNT/A therapy. Arrom et al achieved success in 63% of patients with intravesical BoNT/ A [24] . Also, Wang et al found improvement in 47.5% of patients in their study [25] .…”

Section: Discussionmentioning

confidence: 86%

Efficacy of transcutaneous tibial nerve stimulation in the treatment of bladder pain syndrome

Alkış¹,

Aras²,

Sevim³

et al. 2022

Current Urology

View full text Add to dashboard Cite

show abstract

“…Experimental and Clinical Urology 2023;16(4):164-171; https://doi.org /10.29188/2222-8543-2023-16-4-164-171 мочевого пузыря (ГДМП). У больных с ПСБМП гидродистензию применяют как в виде монотерапии, так и в сочетании с другими методами лечения [16][17][18][19][20]. Установлено, что выполнение ГДМП больным с ПСБМП повышает эффективность пероральной медикаментозной терапии [18] фульгурации гуннеровских поражений [19], внутрипузырной ботулинотерапии [20].…”

Section: Conclusion the Results Of The Study Indicate The Efficacy An...unclassified

Intravesical injections of triamcynolone and bladder hydrodistension in the treatment of patients with primary bladder pain syndrome.

Slesarevskaya,

Kuzmin,

Ignashov

2023

ECU

View full text Add to dashboard Cite

Introduction. Primary bladder pain syndrome (PBPS) is important in urology, due to its high prevalence, negative impact on the quality of life of patients, as well as the lack of effectiveness of existing treatment strategies. The aim of the study was to compare the effectiveness of hydrodistension of the bladder (HD) in combination with intravesical injections of triamcinolone in patients with non-ulcer forms of PBPS. Materials and Methods. In this study participated 68 women with PBPS in the age 38 to 74 years (mean 53.7±9.4 years) were treated and divided into two groups. Patients of the 1st group (n=35) underwent HD in combination with intravesical injections of triamcinolone (in 30 points, 4 mg in 0.5 ml of saline per point, total dose 120 mg). Patients of the 2nd group (n=33) underwent only HD. Treatment efficacy was assessed in 1 and 3 months after the procedure. Results and discussion. One month after treatment a positive effect was observed in 30 (85.7%) patients of the 1st group and 22 (66.7%) patients of the 2nd group. After 3 months of treatment in the 1st group the improvement compared to the baseline remained in 28 (80%) patients and in the 2nd group only in 5 (15.2%) patients. The severity of symptoms in patients of the 1st group during these periods was significantly less than before treatment and also than in patients of the 2nd group. Tolerability of treatment in patients of both groups was good, no side effects were observed in any case. Conclusion. The results of the study indicate the efficacy and good tolerability of the combination of HD and intravesical injections of triamcinolone in patients with non-ulcer forms of PBPS. The therapeutic effect of the combined use of HD and triamcinolone was more pronounced and prolonged than after performing only HD.

show abstract

“…13 Although intradetrusor BTA is a fourth-line treatment for IC/BPS. 5 Uncontrolled 37,38 and randomized [39][40][41][42] clinical trials have documented the efficacy of intradetrusor BTA for IC/BPS. Trigone-only injections of BTA have been shown to be effective in refractory OAB, 43 meanwhile no study has compared trigone-only against trigone-sparing BTA in IC/BPS.…”

Section: Botulinum Toxin a (Bta)mentioning

confidence: 99%

Pathophysiology, assessment, and treatment of overactive bladder symptoms in patients with interstitial cystitis/bladder pain syndrome

Dobberfuhl

2022

Neurourology and Urodynamics

View full text Add to dashboard Cite

Introduction Interstitial cystitis/bladder pain syndrome (IC/BPS) is prevalent, difficult to treat, and has close symptom overlap with overactive bladder (OAB). A review of the pathophysiology, assessment, and treatment of IC/BPS patients with overlapping OAB symptoms has not been summarized recently in the published literature. Methods A review of the published literature on the overlap of IC/BPS and OAB was conducted using MeSH terminology (1992–2022). Results The pathophysiology of IC/BPS is not fully understood. Animal research has found the bladder trigone and base are richly populated by afferent fibers, including many small unmyelinated C‐fibers that may be upregulated in IC/BPS. Successful therapies with multimodal effects on OAB symptoms in patients with IC/BPS are likely to exert beneficial effects on both pain and lower urinary tract symptoms. Potentially efficacious therapies for the treatment of OAB in IC/BPS include pelvic floor physical therapy, oral pharmacotherapy (antimuscarinics and beta‐3 agonists), sacral neuromodulation, percutaneous tibial nerve stimulation, and botulinum toxin A (BTA). Antimuscarinics and beta‐3 agonists have yielded partial efficacy in IC/BPS, although may help differentiate symptoms of OAB from those associated with IC/BPS. The transvaginal trigone treatment (T3) intradetrusor injection approach allows for delivery of therapeutics to the bladder without the need for a cystoscope and appears to be feasible. Conclusions Further research is needed to understand the pathophysiology of IC/BPS and symptom overlap with OAB, which in turn should enable the development of more personalized therapeutics.

show abstract

Onabotulinumtoxin a injection with or without hydrodistension for treatment of bladder pain syndrome

Cited by 4 publications

References 23 publications

Efficacy of transcutaneous tibial nerve stimulation in the treatment of bladder pain syndrome

Efficacy of transcutaneous tibial nerve stimulation in the treatment of bladder pain syndrome

Intravesical injections of triamcynolone and bladder hydrodistension in the treatment of patients with primary bladder pain syndrome.

Pathophysiology, assessment, and treatment of overactive bladder symptoms in patients with interstitial cystitis/bladder pain syndrome

Contact Info

Product

Resources

About